press release-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

news press release media report

year:

select

press release

15 march 2021

alphamab oncology appoints former head of r&d biopharma in china for merck dr. johannes nippgen as chief medical officer dr. nippgen is responsible for clinical development and translational research. he will also contribute to r&d strategy and global cooperation.
11 march 2021

alphamab oncology to present clinical data of pd-l1/ctla-4 bispecific antibody kn046 combined with nab-paclitaxel in the treatment of mtnbc at the aacr 2021 the results show that kn046 is well tolerated and effective as a treatment for advanced triple-negative breast cancer, especially in pd-l1-positive tnbc patients, showing a progression-free survival (...
09 march 2021

alphamab received u.s. fda ind clearance to initiate a phase ii pivotal clinical trial of kn046 (kn046-205, enreach-thymic) in the u.s. kn046 was granted the orphan drug designation by the fda for the treatment of thymic epithelial tumors,and the phase ii pivotal clinical trial of kn046 for the treatment of thymic carcinoma completed ...
08 february 2021

first patient dosed in phase i/ii clinical study of pd-l1/ctla-4 bispecific antibody kn046 in combination with donafenib for the treatment of advanced & metastatic hepatocellular carcinoma（hcc） aiming to evaluate the safety, tolerability and efficacy of kn046 in combination with donafenib in patients with advanced & metastatic hepatocellular carcinoma(hcc).
01 february 2021

data from two clinical studies of pd-l1/ctla-4 bispecific antibody kn046 presented at the 21st world conference on lung cancer (wclc 2020) the phase iii pivotal clinical trial of kn046 as first-line treatment of squamous nsclc (enreach-lung-01) and the phase ii international registration clinical trial for the treatment of advanced thymi...
19 janurary 2021

nmpa grants priority review to the bla for envafolimab(kn035) as the world's first subcutaneous pd-(l)1 inhibitor,envafolimab could be an innovative treatment option for cancer patients and improve their quality of life.
18 janurary 2021

the preliminary clinical efficacy and safety of kn046 plus chemo-radiation therapy in recurrent and metastatic esophageal squamous cell carcinoma presented at asco gi we look forward to seeing more positive data and ultimately enhancing the treatment effect and improving the patients' quality of lives who with esophageal cancer in china and the world.
15 janurary 2021

alphamab oncology announced first patient dosed in enreach-thymic – a phase ⅱ registration clinical study of kn046 for the treatment of advanced thymic carcinoma dosing of the first patient in this phase ii registration study is another important milestone in the global development for kn046. we expect that this innovative therapeutics become a breakthrough th...
06 janurary 2021

alphamab oncology wins the "most valuable medical and pharmaceutical company " at “the 5th annual awards ceremony of hong kong golden stock” alphamab oncology is winning of this award demonstrates the industry's attention and recognition of the company's r&d and operation advantages, and it also affirms the company's long-te...
30 december 2020

alphamab oncology is officially included in southbound stock connect this means that mainland institutional investors and individuals who meet the conditions can purchase alphamab oncology shares through southbound connect.